Cancer BiologybioRxivPreprint
The novel curcumin analogue AKT-100 targets both mutant p53 and STAT3 in gynecologic cancer cells
Geneva L. Williams, Lane E. Smith, Jamie L. Padilla…·Kimberly Kay Leslie
This paper develops AKT-100, a curcumin analogue that targets mutant p53 and STAT3 in gynecologic cancer cells, showing cytotoxicity and synergy with existing therapies.
1 citation